Sectoral Capsule-Anti Diabetic Drugs Market in India (2009 - 2018)
Anti-diabetic drugs are the fastest growing segment, after oncology, in India’s therapeutics market.Thus the anti – diabetic drugs market is expected to grow at a CAGR of 11.30 percent from 2013 to2018. Rise in obese and geriatric population, innovation of new drugs, rapid market adoption ofdrugs and rising income are driving the growth of the market. Due to changes in lifestyle, evenchildren of 13 - 14 years are succumbing to diabetes. These factors offer great opportunities fordomestic and foreign pharmaceutical players.
Some of the high selling anti-diabetic drugs in the Indian market are - Biguanides, Gliclazide,Gliclazide with metformine, Rosiglitazone and Pioglitazone. Human Mixtard 30/70 is the largestselling diabetic insulin in India. The anti-diabetic drugs market in India is highly fragmented, with alarge number of players. Foreign players such as Novo Nordisk, Eli Lily and GlaxoSmithKline are rulingthe market. Presently, many domestic players are trying to carve a slice for themselves through thelaunch of new drugs and refined research and development.
The Indian anti-diabetic drugs market has huge growth potential on the back of increasing agingpopulation, changing lifestyles, newer and better drugs and wide-ranging health insurance policiescovering diabetes.